How do you decide between treating with neoadjuvant nivolumab/ipilimumab versus neoadjuvant pembrolizumab for patients with resectable, clinical node + Stage III melanoma given the NADINA trial results?

Answer from: Medical Oncologist at Academic Institution

The NADINA trial (NCT04949113) has clearly established that the neoadjuvant approach affords a better EFS in patients with clinical stage III melanoma. However, there is no direct comparison between anti-PD1 monotherapy and dual checkpoint inhibition in the neoadjuvant setting. I do not think that s...

Comments

Medical Oncologist at SSM Health Medical Group
Most of the patients referred to me from dermatolo...

Medical Oncologist at University Hospitals
Dr. @Lam, This trial, and other neoadjuvant trial...

Medical Oncologist at SSM Health Medical Group
Yes, most of the cases I was referred to are found...

Please select the option that best describes you:

How do you decide between treating with neoadjuvant nivolumab/ipilimumab versus neoadjuvant pembrolizumab for patients with resectable, clinical node + Stage III melanoma given the NADINA trial results?

Related Questions